Literature DB >> 8972484

Mechanisms of tumor-induced immunosuppression: evidence for contact-dependent T cell suppression by monocytes.

M L Jaffe1, H Arai, G J Nabel.   

Abstract

BACKGROUND: The progressive growth of tumors in mice is accompanied by down-regulation of specific T cell responses. The factors involved in this suppression are not completely understood. Here, we have developed a model to examine the role of host immune effector cells in the inhibition of T cell function. In this model, progressive growth of a colon carcinoma line, CT26, is accompanied by loss of T cell response to alloantigens in both cytolytic and proliferation assays.
MATERIALS AND METHODS: The CT26 tumor was inoculated into BALB/c syngeneic mice. Tumor growth, cytolytic T cell responses, lymphocyte proliferation, and flow cytometric analysis was performed in tumor-bearing animals 7 or 28 days after tumor inoculation.
RESULTS: Spleen cells from tumor-bearing mice were found to suppress the proliferative response of spleen cells from normal mice to alloantigens. Examination of the spleen cell population by FACS analysis revealed an increase in the percentage of monocytes as defined by expression of CD11b, the Mac-1 antigen. Removal of the Mac-1-positive cells from the tumor-bearing hosts spleen relieved suppression of the tumor-bearing mouse spleen cell proliferative response to alloantigens, and addition of the Mac-1-positive enriched cells suppressed proliferation of normal T cells in response to alloantigens. Cell contact was required for this inhibition.
CONCLUSIONS: Tumor induction of suppressive monocytes plays an important role in the general immunosuppression noted in animals bearing CT26 tumors. Identification of the mechanisms responsible for this effect and reversal of tumor-induced macrophage suppression may facilitate efforts to develop effective immunotherapy for malignancy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972484      PMCID: PMC2230136     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  21 in total

Review 1.  The suppressor-cell network in cancer (first of two parts).

Authors:  S Broder; T A Waldmann
Journal:  N Engl J Med       Date:  1978-12-07       Impact factor: 91.245

2.  Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.

Authors:  T Tada; S Ohzeki; K Utsumi; H Takiuchi; M Muramatsu; X F Li; J Shimizu; H Fujiwara; T Hamaoka
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

3.  Engagement of CD14 on human monocytes terminates T cell proliferation by delivering a negative signal to T cells.

Authors:  K H Lue; R P Lauener; R J Winchester; R S Geha; D Vercelli
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

4.  Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor.

Authors:  Y X Fu; G Watson; J J Jimenez; Y Wang; D M Lopez
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

5.  Inhibition of the reactive proliferation of lymphocytes by activated macrophages: the role of nitric oxide.

Authors:  S Denham; I J Rowland
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

6.  Modification of host antitumor defense mechanisms in mice by progressively growing tumor.

Authors:  D L Maccubbin; K F Mace; M J Ehrke; E Mihich
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

7.  Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.

Authors:  R S Parhar; P K Lala
Journal:  J Leukoc Biol       Date:  1988-12       Impact factor: 4.962

8.  Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms.

Authors:  G A Watson; Y X Fu; D M Lopez
Journal:  J Leukoc Biol       Date:  1991-02       Impact factor: 4.962

9.  Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity.

Authors:  I Bursuker; R J North
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

10.  Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex.

Authors:  T Aoe; Y Okamoto; T Saito
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  9 in total

1.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

2.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  Tumor-derived HLA-G1 acquisition by monocytes through trogocytosis: possible functional consequences.

Authors:  Channakeshava Sokke Umeshappa; Jim Xiang
Journal:  Cell Mol Life Sci       Date:  2010-10-26       Impact factor: 9.261

Review 4.  Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Authors:  Sabrin Husein Albeituni; Chuanlin Ding; Jun Yan
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

5.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.

Authors:  V Bronte; M Wang; W W Overwijk; D R Surman; F Pericle; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

6.  Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.

Authors:  K Wiers; M A Wright; K Vellody; M R Young
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

7.  Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.

Authors:  Alexander L Rakhmilevich; Mark J Baldeshwiler; Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Nicholas A Kalogriopoulos; David S Koslov; Nico Van Rooijen; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-03-06       Impact factor: 6.968

8.  CD11b⁺, Ly6G⁺ cells produce type I interferon and exhibit tissue protective properties following peripheral virus infection.

Authors:  Matthew A Fischer; Michael L Davies; Irene E Reider; Erica L Heipertz; Melanie R Epler; Janet J Sei; Molly A Ingersoll; Nico Van Rooijen; Gwendalyn J Randolph; Christopher C Norbury
Journal:  PLoS Pathog       Date:  2011-11-10       Impact factor: 6.823

9.  Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy.

Authors:  Yuk-Wah Tsang; Cheng-Chung Huang; Kai-Lin Yang; Mau-Shin Chi; Hsin-Chien Chiang; Yu-Shan Wang; Gabor Andocs; Andras Szasz; Wen-Tyng Li; Kwan-Hwa Chi
Journal:  BMC Cancer       Date:  2015-10-15       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.